SCREENS for Cancer Act of 2025
Summary
The SCREENS for Cancer Act reauthorizes and expands national cancer screening programs for 2026-2030. This creates a structural volume tailwind for Labcorp ($LH) and Quest Diagnostics ($DGX) as the primary processors of screening lab work. Both stocks have been down over the past month on broader market weakness, not bill-specific news — the authorization provides a real federal program pipeline for incremental testing revenue once appropriations are secured.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2381 reauthorizes a proven federal cancer screening program serving 6.4M+ patients, creating a structural volume tailwind for diagnostic labs
- 2.Authorization ≠ appropriation — actual federal money requires a separate appropriations bill, but program has long bipartisan history
- 3.Companion bill in Senate (S1866) increases passage probability through 119th Congress
Market Implications
Labcorp ($LH) and Quest Diagnostics ($DGX) are the direct beneficiaries of expanded NBCCEDP screening volumes. Both stocks have declined ~4-5% over the past week as part of a broader healthcare selloff, not a bill-specific signal. The authorization provides a federal program revenue pipeline that will sustain incremental testing volumes through 2030 once funded. Investors should watch appropriation markup sessions for the actual dollar amounts. The 57 cosponsors and companion bill indicate meaningful bipartisan support, reducing legislative risk. Centene ($CNC), despite being up 63% over 30 days on its own earnings news, is a managed care operator not directly tied to NBCCEDP lab reimbursement and should not be included in this trade.
Full Analysis
The SCREENS for Cancer Act of 2025 (HR2381) was introduced on March 26, 2025 by Rep. Morelle (D-NY) with 57 cosponsors. It reauthorizes the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for fiscal years 2026 through 2030, expanding the program's scope. The bill has been referred to the House Committee on Energy and Commerce and is in early legislative stage. A companion bill (S1866) has also been introduced in the Senate, increasing the probability of eventual passage.
The money trail: This is an authorization bill — it sets policy and spending ceilings, but does NOT appropriate actual money. Actual funding requires a separate HHS appropriations bill. However, NBCCEDP is a well-established program (created 1991) with bipartisan support, having served 6.4M+ people and provided 16.5M+ screening exams. Reauthorization signals continued federal commitment to cancer screening, which directly benefits the two dominant national lab processors: Labcorp and Quest Diagnostics. The bill text does not specify a new spending ceiling amount, so the incremental revenue will depend on the actual appropriations level.
The market data shows $LH down 4.79% and $DGX down 4.39% over the past 7 days as of the most recent data, but this reflects broader market weakness (HCA, a hospital operator, has dropped 9.61% over 30 days). The recent selloff is not bill-specific. Labcorp actually recovered 2.76% on April 30 alone, closing at $264.23 after hitting a 7-day low of $257.14 on April 29. Quest hit $189.32 on April 29 and bounced back to $195.46 on April 30.
The timeline: The bill must pass the House Energy and Commerce Committee, then the full House, then the Senate (where companion bill S1866 is pending), then be signed into law. Given the bipartisan nature of cancer screening programs, passage in the current Congress is likely but not guaranteed. Actual revenue impact for lab companies will lag by 12-24 months, as appropriations and state program expansions take time.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Program reauthorization and expansion of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for fiscal years 2026-2030
Who must act
State health departments and clinics administering NBCCEDP screenings
What happens
Increased volume of breast and cervical cancer screening lab tests reimbursed through the program, which serves over 6.4M people historically and is expected to expand
Stock impact
Labcorp processes a substantial share of NBCCEDP lab work through its clinical diagnostics segment, which generates approximately $4B in annual revenue from routine clinical testing. Expanded screening volumes directly increase test requisitions for breast and cervical cancer pathology, Pap smears, HPV testing, and mammography-related lab analysis. This is a volume-driven revenue uplift with high incremental margin given fixed lab infrastructure.
What the bill does
Program reauthorization and expansion of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for fiscal years 2026-2030
Who must act
State health departments and clinics administering NBCCEDP screenings
What happens
Increased volume of breast and cervical cancer screening lab tests reimbursed through the program, which serves over 6.4M people historically and is expected to expand
Stock impact
Quest Diagnostics is the other dominant national clinical lab provider, processing a similar volume of NBCCEDP screening tests through its diagnostic services network. Expanded screening directly increases Pap test, HPV test, and breast cancer biomarker testing volumes. Quest's clinical laboratory revenue (~$7B annually) benefits from incremental volume at high incremental margins.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
ASAP Act
CHOICE for Veterans Act of 2025
Supporting Healthy Moms and Babies Act
Reducing Hereditary Cancer Act
Thyroid Disease CARE Act of 2025
Increasing Access to Lung Cancer Screening Act
Access to Breast Cancer Diagnosis Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →